ECSP20039610A - Anticuerpos anti-alfa sinucleína - Google Patents

Anticuerpos anti-alfa sinucleína

Info

Publication number
ECSP20039610A
ECSP20039610A ECSENADI202039610A ECDI202039610A ECSP20039610A EC SP20039610 A ECSP20039610 A EC SP20039610A EC SENADI202039610 A ECSENADI202039610 A EC SENADI202039610A EC DI202039610 A ECDI202039610 A EC DI202039610A EC SP20039610 A ECSP20039610 A EC SP20039610A
Authority
EC
Ecuador
Prior art keywords
alpha
antibodies
sinuclein
alpha synuclein
present
Prior art date
Application number
ECSENADI202039610A
Other languages
English (en)
Inventor
Kerry Louise Tyson
David James Mcmillan
Lichtervelde Lorenzo De
Terence Seward Baker
Peter Charles Elliott
Daniel John Lightwood
Marco Kriek
Patrick Downey
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of ECSP20039610A publication Critical patent/ECSP20039610A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a anticuerpos que se unen a alfa sinucleína y fragmentos de los mismos capaces de unirse a alfa sinucleína como un monómero y en fibrillas y prevenir la agregación de alfa sinucleína inducida por fibrillas de alfa sinucleína. Los anticuerpos de la presente invención son para su uso en el tratamiento de alfa sinucleinopatías, incluyendo la enfermedad de Parkinson.
ECSENADI202039610A 2017-12-15 2020-07-14 Anticuerpos anti-alfa sinucleína ECSP20039610A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720970.1A GB201720970D0 (en) 2017-12-15 2017-12-15 Antibodies

Publications (1)

Publication Number Publication Date
ECSP20039610A true ECSP20039610A (es) 2020-08-31

Family

ID=61008785

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202039610A ECSP20039610A (es) 2017-12-15 2020-07-14 Anticuerpos anti-alfa sinucleína

Country Status (23)

Country Link
US (2) US11292831B2 (es)
EP (1) EP3724228A1 (es)
JP (1) JP7326281B2 (es)
KR (1) KR20200099168A (es)
CN (1) CN111655727A (es)
AU (1) AU2018382527A1 (es)
BR (1) BR112020010508A2 (es)
CA (1) CA3084106A1 (es)
CL (1) CL2020001607A1 (es)
EA (1) EA202091482A1 (es)
EC (1) ECSP20039610A (es)
GB (1) GB201720970D0 (es)
IL (2) IL275223B2 (es)
MA (1) MA51134A (es)
MX (1) MX2020005810A (es)
PE (1) PE20201062A1 (es)
PH (1) PH12020551006A1 (es)
SG (1) SG11202004740RA (es)
TN (1) TN2020000077A1 (es)
TW (2) TW202346343A (es)
UY (1) UY38012A (es)
WO (1) WO2019115671A1 (es)
ZA (2) ZA202003414B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2021055881A1 (en) * 2019-09-20 2021-03-25 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof
AU2020394842A1 (en) * 2019-12-04 2022-06-30 Ac Immune Sa Novel molecules for therapy and diagnosis
JP2023536647A (ja) 2020-08-07 2023-08-28 エルジー・ケム・リミテッド 熱可塑性樹脂組成物
CN113912715B (zh) * 2021-12-15 2022-03-01 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白抗体及其相关产品和应用
WO2023221892A1 (zh) * 2022-05-20 2023-11-23 长春金赛药业有限责任公司 抗α-Synuclein抗体及其用途
CN115043927B (zh) * 2022-06-17 2024-03-19 武汉大学 针对抗α-突触核蛋白K80Hcy抗体的抗原肽及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU2002221132A1 (en) 2000-12-13 2002-07-01 Taisho Pharmaceutical Co. Ltd. Novel antibody
WO2003045128A2 (en) 2001-11-21 2003-06-05 New York University SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2008103472A2 (en) 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
ES2640669T3 (es) 2003-05-19 2017-11-03 Prothena Biosciences Limited Fragmentos truncados de alfa-sinucleína en enfermedad con cuerpos de lewy
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
WO2007021255A1 (en) * 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
PT3067066T (pt) * 2007-02-23 2019-06-17 Univ California Prevenção e tratamento da doença sinucleinopática e amiloidogénica
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CN101289665A (zh) * 2007-04-18 2008-10-22 复旦大学 一种建立抗帕金森病动物模型的方法
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
PL2949666T3 (pl) 2008-12-19 2019-07-31 Biogen International Neuroscience Gmbh Ludzkie przeciwciała przeciwko alfa-synukleinie
CN106397588B (zh) 2010-02-26 2020-09-08 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
US20140309172A1 (en) 2010-11-05 2014-10-16 Dagmar Ringe Ice inhibiting compounds and uses thereof
DE102011008153B4 (de) 2011-01-08 2018-08-09 Aj Roboscreen Gmbh Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
JP5775974B2 (ja) 2011-10-28 2015-09-09 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
WO2015075635A2 (en) 2013-11-19 2015-05-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
CN111499743B (zh) 2013-11-21 2024-01-12 豪夫迈·罗氏有限公司 抗-α-突触核蛋白抗体及使用方法
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015179867A1 (en) 2014-05-23 2015-11-26 University Of South Florida Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinson's disease
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
AU2015314783B2 (en) 2014-09-11 2021-10-21 Amprion, Inc. Detection of misfolded proteins
WO2016040905A1 (en) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded alpha synuclein protein
WO2016040903A1 (en) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded amyloid beta protein
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
DK3341725T3 (da) 2015-08-25 2021-09-06 Prothena Biosciences Ltd Fremgangsmåder til detektering af phosphoryleret alpha-synuklein
CA3004349A1 (en) 2015-11-23 2017-06-01 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
WO2017176835A2 (en) 2016-04-06 2017-10-12 Imago Pharmaceuticals, Inc. Therapeutic antibodies for treatment of neurodegeneration
PE20190440A1 (es) 2016-06-02 2019-03-27 Medimmune Ltd Anticuerpos a la alfa-sinucleina y usos de los mismos
GB201611840D0 (en) 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
US20190194324A1 (en) 2016-08-23 2019-06-27 The Johns Hopkins University THERAPEUTIC USES OF LAG3 THE (alpha)-SYNUCLEIN TRANSMISSION RECEPTOR
MA46836A (fr) 2016-11-15 2019-09-25 H Lundbeck As Agents, utilisations et procédés pour le traitement d'une synucléinopathie
US20180134775A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (7A11)
US20180134776A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (4H6)
US20180134777A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (11D12)
US20190315846A1 (en) 2016-12-12 2019-10-17 The Michael J. Fox Foundation For Parkinson's Research Antibodies to Human Alpha-Synuclein
WO2018109058A1 (en) 2016-12-16 2018-06-21 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CA3049110A1 (en) 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
JP2020504151A (ja) 2017-01-09 2020-02-06 カリフォルニア インスティチュート オブ テクノロジー パーキンソン病の診断および治療薬における腸内微生物叢の使用
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
JOP20190227A1 (ar) 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
JP7308154B2 (ja) 2017-05-16 2023-07-13 アンプリオン、インコーポレイテッド ミスフォールドタウタンパク質の検出
WO2018237338A1 (en) 2017-06-23 2018-12-27 Denali Therapeutics Inc. ANTI-ALPHA-SYNCUCIN ANTIBODIES AND METHODS OF USE

Also Published As

Publication number Publication date
CL2020001607A1 (es) 2020-10-02
IL275223B1 (en) 2023-07-01
ZA202106370B (en) 2023-06-28
CN111655727A (zh) 2020-09-11
US20210101964A1 (en) 2021-04-08
KR20200099168A (ko) 2020-08-21
TW202346343A (zh) 2023-12-01
PE20201062A1 (es) 2020-10-16
MX2020005810A (es) 2020-08-20
IL275223B2 (en) 2023-11-01
US11292831B2 (en) 2022-04-05
RU2020123300A (ru) 2022-01-18
US20220340648A1 (en) 2022-10-27
MA51134A (fr) 2021-03-24
BR112020010508A2 (pt) 2020-11-24
IL303672A (en) 2023-08-01
EA202091482A1 (ru) 2020-09-10
EP3724228A1 (en) 2020-10-21
GB201720970D0 (en) 2018-01-31
CA3084106A1 (en) 2019-06-20
IL275223A (en) 2020-07-30
AU2018382527A1 (en) 2020-07-16
SG11202004740RA (en) 2020-06-29
ZA202003414B (en) 2022-03-30
TW201927810A (zh) 2019-07-16
RU2020123300A3 (es) 2022-01-18
PH12020551006A1 (en) 2021-09-06
TWI806940B (zh) 2023-07-01
TN2020000077A1 (en) 2022-01-06
WO2019115671A1 (en) 2019-06-20
JP7326281B2 (ja) 2023-08-15
JP2021507693A (ja) 2021-02-25
UY38012A (es) 2019-07-31

Similar Documents

Publication Publication Date Title
ECSP20039610A (es) Anticuerpos anti-alfa sinucleína
ECSP20039623A (es) Anticuerpos anti alfa-sinucleína
CL2019003636A1 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson.
CO2017002719A2 (es) Anticuerpos anti-glucagón
CO2017012974A2 (es) Anticuerpos de unión a tau
DOP2022000172A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
CL2017003404A1 (es) Compuestos antibacterianos
CL2019003800A1 (es) Métodos para tratar la enfermedad de huntington.
CR20170060A (es) Anticuerpos anti tigit
CL2019001465A1 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip.
CO2017012971A2 (es) Anticuerpos de unión a tau
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
UY34988A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
AR102658A1 (es) Composición para el tratamiento de telas
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112015024860A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
CL2019003557A1 (es) Anticuerpos anti-trkb.
CR20170376A (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida
AR114808A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA
AR120118A2 (es) Anticuerpos anti tigit
BR112016029044A2 (pt) ácido 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-carboxílico [(s)-1-carbamoil-2-(fenil-pirimi¬din-2-il-amino)-etil]-amida para utilização no tratamento de dor associada à osteoartrite
ES2578708A1 (es) Plantilla para el tratamiento de la celulitis y la grasa